---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-029557"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:43:41.957039+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics Q2 2022 net loss $9.7M; secures $60M credit line; trial enrollment 230 patients randomized

## Summary
- Net loss applicable to common stockholders of $9.7M ($0.16/shr) vs $8.5M ($0.15/shr) in Q2 2021.
- R&D expenses rose to $8.1M from $6.5M, driven by NAVIGATE trial costs.
- Cash and equivalents $24.2M as of June 30, 2022; $60M line of credit from Richard Uihlein available.
- NAVIGATE trial: 230 patients randomized, 70 in screening; enrollment expected to complete Q4 2022.
- Planning to file IND with FDA for belapectin plus Keytruda in head and neck cancer.

## SEC filing metadata
- accession: 0001140361-22-029557
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036122029557/0001140361-22-029557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036122029557/brhc10040754_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-029557
- JSON: https://secwatch.observer/filing/0001140361-22-029557.json
- Plain text: https://secwatch.observer/filing/0001140361-22-029557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.